Identification of tumour cells in CSF using monoclonal antibodies

Monoclonal antibodies may modulate immune and/or biological responses alone, or as carriers of specific agents. Monoclonal antibodies directed against tumours may be indirectly cytotoxic by modulation of antibody-dependent, cell-mediated cytotoxicity or complement-mediated cytotoxicity. Monoclonal antibodies directed against certain tumour cell receptors may alter the biological behaviour of tumour cells such as blocking or downregulation of growth factors essential to tumour cell proliferation. Monoclonal antibodies directed to certain receptors on host immune cells. such as the CD3 receptor on T lymphocytes. may activate those cells and increase their cytotoxicity. Antitumour monoclonal antibodies can serve as carriers of interferons, interleukin-2, tumour necrosis factor and other lymphokines and cytokines to modulate selectively the cytotoxic potential of immune cells in the vicinity of tumour cells. Cytotoxic chemotherapy agents conjugated to antitumour monoclonal antibodies may be processed differently so that they bypass certain mechanisms of drug resistance. The penultimate application of monoclonal antibodies in cancer therapy is to combine various monoclonal antibodies and immunoconjugates for selective combination therapy based on known antigenic tumour cell determinants and the status of the host immune system.

Download Full-text

Enhanced recognition of human colorectal tumour cells using combinations of monoclonal antibodies

British Journal of Cancer ◽

10.1038/bjc.1989.379 ◽

1989 ◽

Vol 60 (6) ◽

pp. 855-860 ◽

Cited By ~ 8

Author(s):

LG Durrant ◽

RA Robins ◽

KC Ballantyne ◽

RA Marksman ◽

JD Hardcastle ◽

...

Keyword(s):

Monoclonal Antibodies ◽

Tumour Cells ◽

Colorectal Tumour

Download Full-text

Antibody-based immunotherapy in high-risk neuroblastoma

Expert Reviews in Molecular Medicine ◽

10.1017/s1462399407000518 ◽

2007 ◽

Vol 9 (34) ◽

pp. 1-21 ◽

Cited By ~ 12

Author(s):

Erik Johnson ◽

Shannon M. Dean ◽

Paul M. Sondel

Keyword(s):

Monoclonal Antibodies ◽

High Risk ◽

Advanced Disease ◽

Treatment Approach ◽

Tumour Cells ◽

Radioactive Isotopes ◽

Intermediate Risk ◽

Chemotherapeutic Drugs ◽

Blocking Antibodies ◽

Made In

AbstractAlthough great advances have been made in the treatment of low- and intermediate-risk neuroblastoma in recent years, the prognosis for advanced disease remains poor. Therapies based on monoclonal antibodies that specifically target tumour cells have shown promise for treatment of high-risk neuroblastoma. This article reviews the use of monoclonal antibodies either as monotherapy or as part of a multifaceted treatment approach for advanced neuroblastoma, and explains how toxins, cytokines, radioactive isotopes or chemotherapeutic drugs can be conjugated to antibodies to enhance their effects. Tumour resistance, the development of blocking antibodies, and other problems hindering the effectiveness of monoclonal antibodies are also discussed. Future therapies under investigation in the area of immunotherapy for neuroblastoma are considered.

Download Full-text